Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | BMC Cancer

Fig. 1

From: IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis

Fig. 1

Overexpression of IAP members, TRAIL receptors DR4, DR5 and BCL-2 members in colorectal adenocarcinoma cell lines: DLD-1 (lane 2), HCT116 (lane 3), SW620 (lane 4), HT29 (lane 5), RKO (lane 6) and Colo-205 (lane 7), compared to Caco2, an intermediate colorectal adenoma cell line (lane 1). a: Relative RNA and protein levels of cIAP-1, cIAP-2, XIAP, SURVIVIN, DR4 and DR5 genes were evaluated by Real Time PCR and W.B analysis respectively in colon adenocarcinoma cell lines. The analysis was performed in triplicates and the ± SD is shown. Columns indicate relative RNA levels normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Proteins are quantified against α-Tubulin. b: Protein levels of other (anti)apoptotic factors in colon adenocarcinoma cell lines by W.B. Data are representative for three independent experiments

Back to article page